MCL Literature Feed

Real-world data show BTKi refractoriness and poor in-vivo brexu-cel expansion predict worse survival, identifying high-risk patients for early relapse and highlighting CAR-T kinetics as a key biomarker.

This review summarizes how second-generation BTK inhibitors like zanubrutinib offer improved target selectivity and tolerability over first-generation agents, providing a potentially safer therapeutic option for MCL patients.

This review advocates for using prognostic tools like MIPI and TP53 status to guide risk-adapted therapy in MCL, intensifying for high-risk and de-escalating for low-risk patients.

In relapsed/refractory MCL, the phase 3 SYMPATICO trial established ibrutinib plus venetoclax as superior to ibrutinib alone, significantly improving median progression-free survival by nearly 10 months.

Robotic-assisted bronchoscopy offers a safe, minimally invasive method for biopsying hard-to-reach aortopulmonary lymph nodes, as demonstrated in a case confirming MCL recurrence.

A novel Mcl1-degrading AUTAC compound synergizes with proteasome inhibitors by hijacking the adaptive autophagy response, offering a preclinical strategy to overcome proteasome inhibitor resistance in MCL.

In MCL cells, the RNA processing factor NUDT21 undergoes alternative polyadenylation to evade miRNA-mediated suppression, revealing a novel mechanism of gene regulation that could be a future therapeutic target.

The chemotherapy-free BOVen regimen (zanubrutinib, obinutuzumab, venetoclax) shows high efficacy (88% CR) and deep MRD negativity in previously untreated, high-risk TP53-mutated MCL, a historically chemo-refractory population.

This review outlines management strategies for delayed complications of CAR T-cell therapy in MCL, moving beyond acute CRS and ICANS to improve long-term patient care and outcomes.

A real-world Japanese study identified BTK inhibitor-based therapy and length of hospitalization as the main drivers of increased healthcare costs, providing crucial data for health economic planning.

Fixed-duration glofitamab monotherapy achieves high complete response rates (78%) in heavily pretreated relapsed/refractory MCL, including post-BTKi patients, offering a potent new off-the-shelf immunotherapy.

This case report details the management of severe brexu-cel toxicities, including a rare intestinal perforation, and highlights the use of anakinra for ICANS, emphasizing complex toxicity management.

This case report describes a rare MCL relapse presenting as diabetes insipidus due to CNS involvement of the hypothalamus, highlighting an unusual manifestation of extranodal disease.

Preclinical data shows the TKI anlotinib inhibits MCL proliferation by targeting the PI3K/AKT/mTOR pathway and modulates the tumor microenvironment, identifying a potential new oral therapy for MCL.

Rituximab maintenance after bendamustine-based therapy in MCL patients is associated with worse outcomes from SARS-CoV-2 infection, highlighting a significant infectious toxicity risk for this common regimen.

This case report of late, recurrent neurotoxicity after brexucabtagene autoleucel demonstrates a mechanism of direct CNS infiltration by CAR-T cells, highlighting the need for long-term vigilance.

Pirtobrutinib achieves an 81% overall response rate in MCL patients intolerant to prior covalent BTKis, offering a well-tolerated sequential option to maintain effective BTK pathway inhibition.

A novel electrochemical sensor was developed for highly sensitive bortezomib detection, potentially enabling therapeutic drug monitoring to personalize dosing and manage toxicity in MCL patients.

A rare case of MCL transdifferentiating into a clonally-related T-cell lymphoma demonstrates a novel transformation mechanism where B-cell markers are lost, complicating diagnosis at relapse.

This review highlights stereotyped B-cell receptors in MCL, suggesting common antigen-driven pathways that could provide a basis for molecular subclassification to refine patient risk stratification.

This methods paper details using sensitive qPCR and ddPCR to detect MRD in B-cell lymphomas by targeting Ig gene rearrangements and chromosomal translocations, relevant for MCL's t(11;14).

For younger MCL patients post-transplant, this phase III analysis shows conditional survival improves over time, especially after R-CHOP, providing data for dynamic prognostication and reinforcing intensive induction.

Mantle cell lymphoma can directly cause retinal vascular occlusion leading to ischemic retinopathy, a rare but vision-threatening extramedullary manifestation that clinicians should recognize.

The Australasian Lymphoma Alliance provides consensus guidelines for MCL diagnosis and management, integrating novel therapies and risk-stratification using biomarkers like TP53, blastoid morphology, and high Ki67.

This review of PROTAC design outlines a novel protein degradation technology with potential to overcome resistance to targeted therapies like BTK inhibitors in mantle cell lymphoma.

This SEER database study on anal lymphomas is not relevant to the MCL field, as it includes only one case of mantle cell lymphoma (1.3% of the cohort).

A simulation model using 20 years of real-world data establishes a baseline for lifetime treatment trajectories, crucial for evaluating the cost-effectiveness of new targeted therapies in MCL.

This study confirms that low/negative CD200 and lower CD43 expression by flow cytometry reliably distinguish MCL from CLL, improving routine diagnostic accuracy for B-cell lymphoproliferative disorders.

This first-in-literature case report identifies sclerosing cholangitis as a novel, severe hepatobiliary toxicity of Tecartus CAR-T therapy in a relapsed/refractory MCL patient, expanding the known safety profile.

This large Swedish real-world study on limited-stage MCL demonstrates that radiotherapy-containing frontline regimens are associated with excellent long-term outcomes, supporting a curative-intent, less-intensive approach for this rare subset.